China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy December 30, 2022 08:30 CET Non Regulatory Read more
Number of shares and votes in Calliditas Therapeutics December 30, 2022 08:00 CET Regulatory Read more
Calliditas CEO acquires shares through the exercise of Calliditas’ warrant program 2019/2022 December 20, 2022 21:15 CET Non Regulatory Read more
Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan December 13, 2022 08:00 CET Regulatory Read more
Calliditas to host fireside chat with its China commercial partner, Everest Medicines December 9, 2022 08:00 CET Non Regulatory Read more
Calliditas’ partner Everest Medicine’s New Drug Application for Nefecon is accepted by the China NMPA November 15, 2022 08:00 CET Non Regulatory Read more
Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape November 7, 2022 09:00 CET Non Regulatory Read more
Calliditas Therapeutics’ nomination committee composition for the AGM 2023 October 21, 2022 10:00 CET Regulatory Read more
Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO[®] (budesonide) in IgA Nephropathy October 19, 2022 15:30 CET Non Regulatory Read more
Calliditas’ partner STADA launches the first medicine authorized in the EU for treating primary IgA nephropathy September 20, 2022 14:00 CET Non Regulatory Read more
European Commission approves Kinpeygo® for adults with primary IgA nephropathy July 15, 2022 17:00 CET Regulatory Read more
Calliditas announces additions to the management team July 11, 2022 12:30 CET Non Regulatory Read more
Calliditas Therapeutics establishes a U.S. At-the-Market Program June 28, 2022 23:15 CET Non Regulatory Read more
Issuance and repurchase of C-shares to establish an at-the-market program June 20, 2022 21:15 CET Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) May 19, 2022 16:30 CET Regulatory Read more
Calliditas receives positive CHMP opinion in IgA nephropathy May 19, 2022 14:30 CET Regulatory Read more
First patient randomized in Phase 2 trial in head and neck cancer May 17, 2022 11:00 CET Non Regulatory Read more
Calliditas Therapeutics to participate in upcoming investor conferences May 10, 2022 08:30 CET Non Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) April 14, 2022 08:30 CET Regulatory Read more
Calliditas CEO acquires shares through the exercise of Calliditas’ warrant program 2018/2022 March 24, 2022 12:00 CET Non Regulatory Read more
Calliditas provides a regulatory update on EMA process for Nefecon March 22, 2022 08:00 CET Non Regulatory Read more
Expansion of Everest Medicine’s licence agreement to include South Korea March 14, 2022 07:00 CET Non Regulatory Read more
First patient randomized in pivotal TRANSFORM study with setanaxib February 15, 2022 10:30 CET Non Regulatory Read more
Calliditas Therapeutics Announces Commercial Availability and Initial Sales of TARPEYO™ January 28, 2022 08:00 CET Non Regulatory Read more